COPD - Positive Results Of Seretide Survival Study

GlaxoSmithKline plc
announces preliminary results from the TORCH study (TOwards a Revolution in
COPD Health) which show a 17% relative reduction in mortality over three years
for patients receiving Seretide(TM) 50/500 micrograms (EU) /Advair(R) (US)
(salmeterol/fluticasone propionate) as compared with patients on placebo
(p=0.052*). This is the first study to investigate the effects of
pharmacotherapy on all-cause mortality in patients with COPD. The primary
comparison was between Seretide/Advair and placebo.


Seretide/Advair also reduced the rate of COPD exacerbations by 25%
compared to placebo (p